Story · Medicine & Biotech

Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial

3 outlets · first reported by MedPage Today on · latest · 19 hours of coverage

(MedPage Today) -- NATIONAL HARBOR, Md. -- Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, the phase III SURMOUNT-ADOLESCENTS trial showed. At week... (MedPage Today)

Coverage, in order

  1. first MedPage Today indie study randomized trial
    Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial

    (MedPage Today) -- NATIONAL HARBOR, Md. -- Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, the phase III SURMOUNT-ADOLESCENTS trial showed. At week...

  2. ConscienHealth indie peer-reviewed
    OW2026: Striking BMI Outcomes with Tirzepatide in Teens

    The possibility of life-changing treatment for adolescents with significant obesity is coming into sharp focus at ObesityWeek. New results from the SURMOUNT-ADOLESCENTS trial, presented at OW2026 and published in JAMA yesterday, show striking outcomes with tirzepatide. Perhaps most remarkable…

  3. TrialSite News obscure study peer-reviewed
    Tirzepatide Cuts Teen BMI by 18.5% in JAMA Trial—But What About Safety, Cost and Lifelong Treatment?

    Tirzepatide Cuts Teen BMI by 18.5% in JAMA Trial—But What About Safety, Cost and Lifelong Treatment?

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.